Answers are grounded in this paper and cite their sources.
Brucellosis prediction spans persistent clinical disease, post-treatment recurrence, and transmission across human-animal-environment interfaces. This narrative review distinguishes primary prediction studies from supporting risk-factor evidence and adds a report-based appraisal using PROBAST for individual prognosis and adapted domains for nonclinical models. The evidence is uneven: one reviewed chronicity model showed moderate internal discrimination; relapse evidence chiefly concerns label quality and treatment-related risk factors; and forecasting studies predict reported cases rather than individual infection. Genomic models classify proxy zoonotic labels and require independent confirmation. Different outcome definitions, limited validation, and ascertainment bias prevent pooled estimates or direct performance ranking. We propose a staged One Health framework that begins with routine clinical and surveillance data and adds animal, environmental, or genomic inputs only when accessible and demonstrably useful. The full loop remains a proposal rather than a validated intervention. Priorities are reproducible endpoints, prospective external validation, calibration, feasible cross-sectoral governance, and measured clinical or public-health benefit. Affordability and cost-effectiveness remain hypotheses to be tested.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: